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Opening lecture 
Mr. Janez Potoènik, the EU Commissioner for Science and 
Research, delivered the opening lecture applauding the 
dedication of the EORTC over the past 45 years to the 
promotion and conduct of multidisciplinary cancer research. He 
welcomed the transatlantic partnership between the EORTC, 
the NCI and ASCO as an exemplary approach to the global 
research challenges of cancer. Speaking on the topic of 
European research in cancer, Commissioner Potoènik cited the 
development of the European Research Area that promotes the 
free movement and seamless interaction of researchers; 
reinforces the links between education, research and 
innovation; supports research through the coordination of 
national, regional and European programs and builds mutually 
beneficial international partnerships. 
The EU investment in cancer research, through the 6th 
Framework Programme, spanning 2002--2006, witnessed an 
increase from €18 million to €450 million. The first €70 million of 
a similar amount has already been released under the 7th 
Framework Programme with an emphasis on translational 
research projects that will ‘exploit the European dimension by 
combining resources and complementary competences from 
several European countries, and by encouraging the 
comparison of results and data from the whole of Europe,’ 
according to Commissioner Potoènik. Additional funding has 
also been earmarked by the European Research Council (ERC) 
for a network infrastructure for biotherapy facilities; an European 
bio-banking and bio-molecular resources infrastructure and an 
European advanced translational research infrastructure. 
Commissioner Potoènik urged Member States to work together 
in cancer research, which will be facilitated in part through the 
planned ERA-NET for the coordination of national research 
programmes and an initiative using cancer registries for 
research purposes. The upcoming 2008 Slovenian Conference 
on Cancer ‘The Burden of Cancer -- How Can Be Reduced?’ 
will address ways to improve the structure and coordination of 
cancer research in the EU, increase research funding, translate 
knowledge into applications and include patients in the process 
of cancer research. 
 
Assessment of biomarkers in tumour 
tissues and blood 
The first scientific session of the meeting featured presentations 
highlighting the challenges researchers face working in the area 
of tumour marker assessment and the standards used for the 
collection, storage, transportation and analysis of biospecimens. 
Vital international efforts are ongoing at this time to further 
define the procedures and methods used in the area of 
biobanking to ensure the collection of the highest quality of 
biospecimens and to validate the outcomes of this research. It is 
clear that greater international harmonization  is needed in this 
respect. 
The newly updated ASCO recommendations for the use of the 
tumour marker tests in the prevention, screening, treatment and 
surveillance of breast cancer is one such effort. The 2007 
update includes six new tumour marker categories that are now 
recommended for use in practice based on clinical utility and 
magnitude of benefit. Dan Hayes, the ASCO Committee Co-
Chair pointed out, however, that the routine use of other 
markers such as DNA/ploidy by flow cytometry, p53, cathepsin 
D, cyclin E, proteomics, certain multi-parameter assays, bone 
marrow micro-metastases detection and circulating tumour cells 
cannot be recommended at this time due to a lack of sufficient 
levels of supporting evidence. 
Another set of forthcoming recommendations for the collection 
and handling of bio-specimens prepared by the Blood, FFPE 
and Fresh/Frozen Tissue Working Groups of the NCI-sponsored 
North American Breast Cancer Cooperative Groups and the 
Breast International Group were highlighted by Brian Leyland-
Jones of Emory University School of Medicine. This work aims 
to promote and ensure the standardized collection of high-
quality specimens, guarantee the application of future 
technologies and incorporate these standards into all future 
clinical trial protocols conducted by the Breast International 
Group (BIG) and NCI-Sponsored North American Cooperative 
Groups in an effort to maximize results from specimen-based 
diagnostic testing and research. 
Cancer biobanking from both an American and European 
perspective was discussed. Carolyn Comptom from the National 
Cancer Institute, Bethesda, MD, noted that although 
translational research promises to advance molecular medicine 
for cancer patients, the single biggest current roadblock is the 
lack of sufficient high-quality biospecimen materials needed to 
study the biological complexities of genomics, proteomic and 
metabolomics. The Office of Biorepositories and Biospecimen 
Research (OBBR) at the US National Cancer Institute has 
undertaken several new initiatives to address these issues, 
including biobanking protocols, patients’ consent, biobanking 
workforce education and the establishment of a new field of 
research for biospecimen science. 
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Christian Chabannon (Institut Paoli-Calmettes, Marseilles, 
France) pointed out that in Europe the primarily hospital-based 
biobanking system faces numerous challenges for the collection 
and annotation of high-quality biological materials needed for 
translational research. To address these challenges, local, 
regional and national efforts are being made for specimen 
tracking and management, institutional collaboration to establish 
validated biospecimen collection catalogues, financial support 
for restructuring of biobank facilities and quality assurance 
standards. Current European initiatives such as the Tubafrost, 
EuroBioBank and European Biobanks United Facility are 
significant initiatives towards a more centralized coordinated 
approach to biobanking. 
Gerry Thomas, Imperial College and Wales Cancer Bank 
furthered the debate elaborating on the importance of 
adherence to and the monitoring of quality assurance (QA) 
standard operating procedures (SOPs) for the collection, 
documentation and storage of biospecimens in the development 
of clinical biomarkers. Her recommendations for a system of QA 
include the strict use of and adherence to written SOPs. 
Furthermore, QA at all subsequent stages is required when 
modifying the methods of specimen collection. Additional 
requirements are the need for careful assessment of storage 
time and methods, the appropriate application of technology, 
the most suitable QA depending on the intended use of the 
biological material and the constant need to educate 
researchers. These measures help to ensure a high quality of 
clinical biomarker research. 
The Bavarian Red Cross ‘Blood Donor Biobank,’ in operation 
since 2006, is an example of a well-established biobanking 
system supported by experienced employees and GMP 
facilities, SOPs and QA processes. According to Silke Martin, 
Head of the Blood Donor Biobank, it represents a unique 
opportunity and a new approach for identifying and validating 
tumour markers. Whereas others are only in the start-up 
process of establishing biobanking facilities, this biobank 
already has a repository of over 4 million plasma samples 
prospectively collected from healthy volunteers linked to donor 
health status. The Bavarian experience demonstrates that blood 
banks are ideal cancer research units owing to the ease of 
access, collection, transportation, storage and analysis that 
blood samples provide. Both academic and industry research 
collaborations are currently ongoing to screen for and identify 
potential cancer biomarkers. 
The roundtable discussion addressed the importance of 
harmonization, funding and patient/public support for biobanking 
and tumour marker development. Harmonization  is needed in 
the global standardization  of biobanking activities, the process 
of biomarker validation and the need for improved partnerships 
with key stakeholders to ensure the long-term financial viability 
of biobanking. The global standardization  of biobanking 
requires universal guidelines for biospecimen collection, 
transportation, storage and cataloging. Improved 
communication are needed to ensure the appropriate financial 
support, the availability of biobanking facilities and the 
adaptation of global standards by local institutions that may be 
achieved in part by the support of advocacy groups and the 
public exerting pressure on the politicians. International 
collaboration and harmonization  will ensure the most efficient 
use of funding, the longevity of established facilities and the 
future career of young translational researchers. Biobanking is 
now a part of the evolution of healthcare. Currently, most 
cancer-related healthcare costs occur in the last 6 months of 
life. Biobanking and the development of biomarkers and 
targeted therapies that ‘select’ patients for more tailored 
therapeutic approaches earlier, requires upfront investment but 
will result, not only in a more efficient use of funds but ultimately 
advance the battle to prevent cancer. 
 
Imaging biomarkers 
This session examined the current state of research on the use 
of imaging methods as predictive and treatment response 
biomarkers. Lawrence Schwartz, of Memorial Sloan-Kettering 
Cancer Centre, provided insight into whether size-based 
response criteria are appropriate in today's era of targeted 
therapy. Despite the many advances in imaging technology and 
the use of new targeted therapies (i.e. bevacizumab, erlotinib, 
gefitinib), clinicians today continue to use computed tomography 
(CT) and assess tumour size based on the RECIST or WHO 
criteria. These therapeutic agents, however, induce tumour 
changes in response to therapy that CT may not reliably reflect. 
Early results indicate that volumetric CT calculation, measuring 
tumour central necrosis and cystic change and tumour 
‘ghosting’ in response to treatment may represent future 
response biomarkers that complement current criteria or even 
replace them. 
Wolfgang Weber shared the findings of work done at the 
University of Freiburg, evaluating the utility of FDG-PET to 
predict early treatment response and patient outcome based on 
the ability of FDG-PET to differentiate residual or recurrent 
viable tissue and therapy-induced fibrosis. This ability would 
allow clinicians to personalize patient’s therapy and reduce the 
adverse effects and costs of ineffective or unnecessary 
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treatments. He suggested that FDG-PET could also reduce the 
length of new drug clinical trials via the provision of earlier and 
more accurate measures of tumour therapy response as 
already demonstrated by studies of the c-kit inhibitors for 
gastrointestinal stromal tumours. In these studies, tumour size 
reduction was preceded by metabolic changes. Promising signs 
for the future use of this technology include the recent 
standardization  of FDG-PET imaging that now allows for its use 
at non-research medical centres and the current inclusion of 
FDG-PET response assessment in the International Working 
Group Criteria for lymphoma. 
The PET biomarker research is also ongoing at the University of 
Washington, and David Mankoff discussed the use of FDG-PET 
as functional and molecular imaging markers for selecting 
patient treatment. FDG-PET has shown its value as a biomarker 
of treatment response in studies such as the MUNICON 
gastroesophageal cancer study, which showed the ability of 
FDG-PET to predict early treatment response based on 
metabolic changes. Radiopharmaceuticals can also guide 
treatment selection by quantifying the treatment target and by 
identifying treatment resistance factors. PET can measure 
therapeutic targets such as ER, AR and HER2 molecules in 
breast and prostate cancer, using fluoroestradiol (FES), F-18-
fluorodihydrotestosterone (FDHT) and [Ga-68]-labelled F(9ab') 
trastuzamab fragments. [F-18]-flourosionidazole PET can 
measure tumour hypoxia, a known resistance factor for 
radiotherapy. Tumour drug resistance due to blocked tumour 
drug delivery can be shown by using [C-11]-verapamil to 
measure regional P-glycoprotein transport. PET can also detect 
early treatment response by measuring tumour proliferation 
and/or cell death. New radiopharmaceuticals utilised together 
with conventional and established PET procedures are ideally 
suited for use in the early pre-clinical and phase 0-I testing of 
new targeted therapies but will require appropriate standards of 
testing and validation. 
Gordon Jayson of the Christie Hospital presented an opposing 
view on optimal drug sequencing of combination treatments 
suggesting that by administering cytotoxic agents prior to anti-
angiogenic agents, contrary to current opinion, improved 
therapeutic benefit may be observed. Dynamic contrast-
enhanced MRI (DCE-MRI) has been used as a biomarker to 
evaluate VEGF inhibitors (vascular endothelial growth factor) 
based on change in tumour vascular permeability as measured 
by the leakage of contrast media from the tumour vessels into 
the interstitial space and expressed as Ktrans. Investigators at 
the University of Manchester and the Christie Hospital have 
observed that the anti-angiogenic impact of VEGF inhibitors on 
Ktrans may be regulated by a more widespread effect on the 
VEGF system then currently believed. As the use of anti-
angiogenic drugs becomes more widespread, well-established 
DCE-MRI parameters will be needed. The importance of this 
technology as a ‘response biomarker’ requires its evaluation as 
part of future early clinical studies testing new drugs. 
The roundtable discussion focused on methods to evaluate and 
qualify imaging biomarkers in drug development and their use 
as surrogate markers of clinical benefit. The need for an 
international conference to coordinate the standardization  of 
biomarker imaging is recognized due to the complexity of each 
imaging domain. Imaging-base biomarker work is reproducible 
in small early phase studies however when attempting large 
phase III confirmative trials multiple issues arise that include not 
only the technique of the imaging procedure itself but also 
extend to the scanners used, scanner installation and the use of 
similar algorithms to interpret the results. Progress is being 
made with FDG-PET technology. However, partnership is 
needed with the scanner industry to stimulate further 
development and standardization. Another issue surrounds the 
use of radiopharmaceuticals as biomarker probes and the 
validation process. Each is a therapeutic product in itself and 
therefore requires phase I to III testing with subsequent 
approval for human use. The NCI Cancer Imaging Network 
currently conducts early phase imaging drug studies in this 
respect. The final point raised by the discussants was the need 
for new study designs that define valid endpoints of response 
when testing functional or molecular imaging. Despite the 
advances to date and the promising uses of imaging as 
biomarkers of treatment response, much work lies ahead and 
must be addressed by the combined and coordinated effort of 
all stakeholders. 
 
Tumour biomarker assessment at the gene 
and protein level 
This session provided a broad view of the in-depth knowledge 
underlying the use of biomarkers for the diagnosis, prognosis 
and treatment of various types of cancers. Christos Sotiriou 
from the Institut Jules Bordet presented the results of the first 
and largest meta-analysis conducted of gene expression 
profiles in breast cancer. This study evaluated gene expression 
and clinical data from 2833 breast tumours. The analysis 
showed that the disparity in gene lists studied was attributed to 
patient heterogeneity, the methods of gene profiling and small 
sample size compared to examined gene number resulting in 
sampling variation. Tumours were classified into three main 
subtypes based on ER and ERBB2+ status. ER-/ERBB2- and 
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ERBB2+ tumours were characterized by high proliferation, 
whereas ER+ tumours were more heterogeneous and further 
subdivided into ER+/low/luminal A and ER+/high/luminal B 
subtypes. All examined prognostic signatures, despite gene list 
disparity, had similar performance and the common significant 
factor appeared to be proliferation. All signatures proved 
valuable for prognosticating risk of recurrence in the ER+ 
subgroups and less so for the ER- and ERBB2+ tumours. The 
researchers concluded that breast cancer tumour size and 
nodal status remain important but that an association does exist 
between clinicopathological prognostic factors, expression-
based sub-typing and prognostic signatures. 
Janet Warrington, Affymetrix, Inc., presented the challenges in 
applying genomic technology to molecular diagnostics 
highlighting that despite the use of whole genome gene 
expression assays in cancer studies today, few diagnostic 
assay tests have been developed and approved for widespread 
use. This relates back to assay reproducibility, outcome data 
reliability and whether the gene signature is of any clinical 
relevance. A bottleneck exists in the development process of 
diagnostic assays at the time of clinical validation especially 
with respect to study design. Stefan Michiels noted, ‘the 
prognostic value of published microarray results in cancer 
studies should be considered with caution’ and recommended 
the use of validation by repeated random sampling. 
International standard setting initiatives are currently underway 
in an attempt to expedite the use of micro-array technology in 
clinical studies, trials and diagnostics. The Clinical Laboratory 
Standards Institute and the Microarray Quality Control (MAQC) 
project are attempts at standardising the process of material 
collection and handling, and the testing of assay reproducibility. 
These steps are all needed before the full benefits of genomic 
technology can be derived for not only researchers and 
developers but also ultimately for the patient. 
Samir Khleif presented the FDA perspective for testing and use 
of biomarkers in oncology. He highlighted that ‘few biomarkers 
actually reach clinical use and that a new way of approaching 
biomarker research is urgently needed’. The word biomarker 
was first used in 1965. However, PSA was approved as a 
marker to monitor treatment in 1986 and only in 1994 was 
approved for early detection of prostate cancer. The challenges 
facing biomarker development include laboratory methodology, 
analytical validation, and clinical quantification, cost utility and 
regulatory hurdles. Clinical trial design has also fallen far behind 
compared to the advanced nature of technology and drugs 
tested today. The FDA supports a shift in the way drugs are 
developed, evaluated and assessed for human use, including a 
move away from the conduct of massive-sized clinical trials and 
more towards the study of specific patient subsets and 
personalized  tailored therapies. This approach requires 
partnerships at all stages of drug development and is the focus 
of the current ‘New Federal Health Initiative to Improve Cancer 
Therapy’, which is an attempt to accelerate the development 
and delivery of new cancer treatments for patients. 
The technology and tradeoffs of mining the proteome for 
clinically useful lung cancer signatures was explored by David 
Carbone of Vanderbilt University. The various classes of lung 
cancer each contain many distinct and overlapping subsets, all 
requiring specific analyses to define the optimal therapeutic 
approach. Patients with tumours that express mutant EGFR 
derive a significant benefit from minimally toxic targeted therapy 
such as gefitinib and erlotinib. However, further study of 
potential salvage therapies is required to address the eventual 
emergence of resistance mechanisms. Evaluation of the 
proteome compared to DNA sequence analysis or expression 
arrays has multiple advantages. A complete understanding of 
the proteome would provide information on the mechanism of 
functional dysregulation associated with the development of 
cancer (DNA mutations, rearrangements, transcriptional 
alterations and promoter methylation). In-depth information is 
now obtainable using the improved previously cumbersome 
technology of shotgun proteomics. This approach allows for the 
analysis of single tissue samples, and the identification of 
tumour cell line activated pathways in real time as well as direct 
quantification of specific peptides. Further refinement will permit 
the assessment of individualised risk and aid in the treatment 
decision-making process. 
Elftherios Diamandis discussed novel prognostic and treatment 
biomarkers for patients with ovarian cancer. His group work at 
Mount Sinai Hospital in Toronto has focused on the human 
kallikrein locus that consists of 15 genes with significant 
similarity. They have developed methods to quantify all 
kallikrein proteins in serum and tissue extracts and have 
identified six kallikreins with prognostic value that are 
specifically over-expressed in ovarian cancer (KLK5, KLK6, 
KLK8, KLK10, KLK11, KLK13). Through an elaborate analysis 
of these kallikreins, alone and in combination with other 
biomarkers (CA-125) and clinical parameters, they have 
succeeded in developing a combined marker that is both 
prognostic and predictive of ovarian cancer patient response to 
chemotherapy. High serum levels of KLK6 were associated late 
stage disease, lack of response to chemotherapy and poor 
disease-free and overall survival. KLK6 values were 49 times 
higher when compared to normal ovarian tissue. The use of 
these ovarian-specific kallikrein biomarkers alone or in 
combination with other factors may lead to improved 
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individualized  tailoring of ovarian cancer patient therapy. Other 
cancers also express kallikrein proteins such as kallikrein 3 or 
PSA in prostate cancer and kallikreins 5, 8 and 11 in breast 
cancer. The kallikreins are therefore one of the most promising 
new cancer biomarker families and therefore deserve further 
study. 
 
Molecular markers predictive of therapeutic 
benefit 
The predictive value of response biomarkers has been studied 
in an attempt to individualise patient’s treatments and for the 
selection of more effective therapeutic regimens. These include 
methylated MGMT and EGFR-TKI in glioblastoma, EGFR-TKI 
and ERCC1 in non-small cell lung cancer and pathologic 
complete response in breast cancer. 
Monika Hegi, Centre Hospitalier Universitaire Vaudois (CHUV), 
Switzerland, updated the translational research findings from 
the EORTC trial 26981/NCIC CE.3. This was a randomized   
phase III clinical study evaluating the epigenetic inactivation of 
the MGMT gene as a predictive factor for benefit from adjuvant 
treatment with temozolomide plus radiotherapy compared with 
radiotherapy alone in patients with newly diagnosed 
glioblastoma multiforme (GBM). This study confirmed the 
positive predictive value of the methylated MGMT gene. At 2 
years, 46% of patients who received the combined study 
treatment and whose tumours had a methylated MGMT 
promoter gene survived compared with only 14% of patients 
with an unmethylated MGMT gene (p=0.0001). The 
reproducibility of MGMT as a predictive biomarker will be 
prospectively validated as part of the ongoing 
EORTC/NCI/RTOG (EORTC protocol 26052-22053) phase III 
study comparing conventional adjuvant temozolomide with 
dose-intense temozolomide in patients with newly diagnosed 
glioblastoma. Numerous studies now include the assessment of 
MGMT status because of these findings, one of which is a 
phase III trial evaluating the efficacy of cilengitide in newly 
diagnosed GBM patients with stratification for MGMT status. 
Efforts are underway to identify a corresponding gene signature. 
Ingo Mellinghoff (Memorial Sloan-Kettering Cancer Centre) and 
colleagues have studied possible biomarkers of the EGFR-TKI 
response in GBM. In a retrospective analysis, examining GBM 
tumours from patients treated with signal transduction inhibitors, 
such as the EGFR TKIs erlotinib or gefitinib, clinical response 
was highly correlated with co-expression of tumour suppressor 
PTEN and EGFRvIII in 10%-20% of patients. In a follow-up 
prospective phase I study of patients with molecularly defined 
PTEN deficient GBM tumours, the MTOR inhibitor rapamycin 
was shown to cross the blood--brain barrier. Intra-tumoural drug 
concentrations associated with anti-proliferative activity, similar 
to those observed in PTEN-deficient pre-clinical models, were 
documented however, no drug was identified in the tumour 
cells. Host-related factors (i.e. vasculature) might impede 
tumour cell drug delivery thereby impairing effective mTOR 
inhibition and the anti-proliferative response. In a subset of 
tumours, reactivation of Akt was associated with an inferior 
clinical response, leading the researchers to conclude that 
combination mTOR plus PI3K inhibition may overcome this type 
of drug resistance. 
Bruce Johnson of the Dana-Farber Cancer Institute presented 
the impact of EGFR mutations and the potential application of 
EGFR-TKI treatment response biomarkers in non-small cell lung 
(NSCL) cancer. In NSCL, cancer EGFR mutations lie in exons 
18-21 of the TK domain. A clinical study compared the 
relationship between EGFR gene copy number, EGFR protein 
expression, EGFR mutations and Akt activation status as 
predictive markers for gefitinib therapy in advanced NSCLC. 
High-EGFR gene copy number, as identified by FISH, was 
found to be a potential molecular predictor for gefitinib efficacy 
in advanced NSCLC. Two large randomised studies, one of 
gefitinib (Cappuzzo et al.) and the second, erlotinib (Tsao et al.) 
compared active treatment to placebo in patients with recurrent 
NSCL cancer to determine if EGFR mutation is predictive of 
treatment outcome. Cappuzzo concluded that high-EGFR gene 
copy number identified by FISH might be an effective molecular 
predictor for gefitinib efficacy in advanced NSCLC. However, in 
the Tsao et al. study, multivariate analysis showed that survival 
after treatment with erlotinib was not influenced by EGFR 
expression status. 
Jean-Charles Soria of the Institut Gustav Roussy discussed the 
use of pharmacogenomic criteria, such as ERCC1 status, as a 
predictor of response to chemotherapy. In vitro and clinical data 
show that ERCC1 expression is negatively associated with 
response to cisplatin or oxaliplatin chemotherapy in gastric and 
colon cancer and high-tumour tissue levels of ERCC1 mRNA 
confers cisplatin resistance in ovarian and gastric cancer 
patients. Employing IHC-based ERCC1 protein expression 
analyses, results from the International Adjuvant Lung Cancer 
Trial (IALT) showed that patients with ERCC1 negative tumours 
randomised to adjuvant cisplatin-based chemotherapy had an 
increase in overall survival of 14 months compared to patients 
randomized  to observation, whereas patients with ERCC1-
positive tumours did not show this result. The Genotypic 
International Lung Trial (GILT) by the Spanish Lung Cancer 
Group conducted the first study to use ERCC1 mRNA status to 
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customise chemotherapy in patients with previously treated 
NSCL cancer. Although the results suggest that high levels of 
ERCC1 predict a better outcome with the combination treatment 
of gemcitabine-docetaxel over cisplatin-docetaxel, issues of 
reproducibility and a trial patient drop out rate of 17% 
complicated the interpretation of these results. Two additional 
pharmacogenomic-directed trials in patients with NSCL cancer 
are evaluating the predictive value of ERCC1 status in relation 
to adjuvant cisplatin-gemcitabine (SWOG) or erlotinib with or 
without cisplatin (IFCT) therapy. Future trials will need to be 
pharmacogenomic based and integrate the best biomarkers if 
personalised cancer therapy is to become a reality and to 
explore how cisplatin resistance might be reversed by ERCC1 
target modulation. 
Herve Bonnefoi (Institut Bergonie) and colleagues appear to 
have confirmed the validity of gene expression signatures in a 
large series of patients with ER negative breast tumours treated 
in the randomised phase III EORTC 10994/BIG 00-01 
neoadjuvant clinical trial. Patients received a traditional 
anthracycline-based (FEC) or a taxane-containing regimen 
(TET: docetaxel-›epirubicin/docetaxel). Pathological complete 
response (pCR) defined chemosensitivity. RNA was prepared 
from sections of frozen biopsies taken at diagnosis and 
hybridised to Affymetrix X3P microarrays. A pCR was 
established in tumour samples from 28/66 (FEC) and 27/59 
(TET) patients. In vitro single-agent drug sensitivity signatures 
were combined to obtain anthracyline- or taxane-based 
regimen-specific signatures and were shown to be highly 
predictive of pCR (p<0.0001). It appears that pCR is a good 
surrogate marker for ER negative tumours, and validation of 
these initial findings is planned. 
 
Oral presentation of ‘Best’ Posters 
Three young European researchers presented the results of 
their work in the area of biomarkers and cancer therapeutics. 
Cathy Kelly, a Clinical Oncology Fellow, presented the initial 
findings of research done in the area of breast cancer 
progression-associated biomarkers at the UCD School of 
Biomolecular and Biomedical Science, Conway Institute, 
University College Dublin, Ireland. This group selected 137 
targets for antibody production from a cohort of several hundred 
candidate progression-associated biomarkers by applying a 
novel bioinformatic technique to available DNA microarray 
datasets. The first 32 antibodies produced were screened via 
Western blot and IHC against normal and tumour tissue as well 
as cultured cells represented on tissue microarrays (TMAs). The 
highly optimized  antibodies were screened against a TMA 
constructed from a cohort of 524 cases of breast cancer that 
included all disease stages. Differential staining between normal 
and breast cancer tissue was observed in a quarter of the 32 
antibodies. PDZK1, an oestrogen-responsive gene associated 
with good prognosis showed differential expression between ER 
positive and negative tumour cell lines, confirmed by IHC and 
PDZK1 protein expression was associated with improved 
breast-cancer-specific survival, ER positivity and low-tumour 
grade. The researchers concluded that re-analysis of publicly 
available DNA microarray datasets is a cost-effective method 
for candidate biomarker selection/prioritization, and good quality 
TMAs can be used to validate both prognostic and predictive 
biomarkers. 
Sabine Tejpar and colleagues at the Catholic University of 
Leuven, Belgium, have identified a potential biomarker of 
response to cetuximab therapy in colorectal cancer (CRC). 
Recent reports have shown that metastases from patients 
responding to cetuximab monotherapy show high mRNA 
expression of amphiregulin (AREG) and epriregulin (EREG). 
This group examined AREG and EREG expression by real-time 
quantitative RT-PCR (TaqMan) in FFPE tumour primary CRC 
tissue from patients with irinotecan-resistant metastatic CRC 
treated with cetuximab and irinotecan and correlated expression 
with response and survival. The results confirm that high AREG 
and EREG levels in CRC tissue from the primary site were 
associated with objective response and improved overall 
survival, and further validation of these markers is warranted. 
Marlies Langenberg, Department Medical Oncology, Utrecht 
Medical Center in the Netherlands presented the results of her 
group's evaluation of circulating endothelial progenitor cells 
(CEPC) as biomarkers. CEPC are known to reflect tumour 
angiogenic activity and are therefore of potential use as 
biomarkers in the clinical decision-making process. However, 
CEPC have yet to be validated for routine use due to 
differences in the technical procedures employed for measuring 
CEPC and the significant inter-patient and intra-patient 
variability observed. To address these issues, CEPC were 
measured in over 1000 samples from 450 clinical trial patients 
treated with various modalities and 90 volunteers. Intra-
procedure, intra-patient and inter-patient variability were 
analysed. The results show that flow cytometry is a reliable and 
preferred method of CEPC measurement due to its low intra-
procedure and intra-patient variability and because it enables 
specific phenotypic characterization of cells in stored samples. 
However, although absolute cell number is reflective of 
biological activity, significant inter-patient variability was 
observed, thus prohibiting the use of reference values. These 
 7  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2008, 2:75 
 
findings help to understand the technical issues surrounding the 
use of circulating endothelial progenitor cells as biomarkers, 
and the conclusions are consistent with the most recent ASCO 
recommendations, concerning the use of circulating tumour 
cells as clinical tumour markers. 
 
Conclusions 
This tripartite annual meeting, once again, provided participants 
with a broad overview of the current state of cancer biomarker
research, the clinical application of specific markers in all major 
tumour types and helped to advance and provide direction for 
future biomarker research, thus ensuring continued international 
scientific collaboration between Europe and the United States. 
Planning is already underway for the 2008 ASCO-NCI-EORTC 
Annual Meeting on ‘Molecular Markers in Cancer’ to be held in 
Hollywood, FL, USA, on 30 October–1 November 2008. 
For full access to all meeting oral presentations, the European 
Journal of Cancer meeting abstract supplement, and late-
breaking abstracts, please visit the HIGHLIGHTS section of the 
EORTC website at: www.eortc.be
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